NCT04185272RecruitingNot Applicable
Role of Butyrophilins in Colon Cancers Aggressiveness Evaluation
Institut Paoli-Calmettes1 site in 1 country200 target enrollmentStarted: June 30, 2020Last updated:
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Not Applicable
- Status
- Recruiting
- Sponsor
- Enrollment
- 200
- Locations
- 1
- Primary Endpoint
- evaluation of BTNL3, BTNL8 and BTNL9 expression by transcriptomics and immunohistochemistry
Study Overview
Brief Summary
quantification of BTNL molecules in colon cancer in order to determinate if their could be used as a prognostic marquer
Study Design
- Study Type
- Interventional
- Allocation
- Non Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Basic Science
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Patient is older than 18 years old,
- •Signed participation consent,
- •Non-metastatic colon cancer immediately resectable or metastatic and liver synchronous for which it was decided a combined colic and liver surgery (metastatic patient at the outset) in multidisciplinary consultation meeting.
- •Performance Status (PS) 0 or 1
- •affiliated to the social security or beneficiary
Exclusion Criteria
- •Rectal cancer, colon cancer recurrence
- •Emergency of colon cancer Surgery
- •History of inflammatory disease of the digestive tract (Crohn's disease or ulcerative colitis)
- •Patient who received neoadjuvant therapy other than chemotherapy
- •Patient treated with immune-suppressors or long-course corticosteroids <12 months
- •Pregnant women or likely to be pregnant (without effective contraception) or breastfeeding,
- •Person in urgent situation, person under legal protection measure, or unable to express his / her consent,
- •Impossibility of submitting to the medical examination of the test for geographical, social or psychological reasons
Arms & Interventions
non-metastatic colon cancer
Experimental
Intervention: analysis of BTN and BTNL status (Biological)
metastatic colon cancer
Experimental
Intervention: analysis of BTN and BTNL status (Biological)
Outcomes
Primary Outcomes
evaluation of BTNL3, BTNL8 and BTNL9 expression by transcriptomics and immunohistochemistry
Time Frame: 8 years
healthy and cancerous colon ad metastasis (if applicable) will be analysed by
Secondary Outcomes
No secondary outcomes reported
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Completed
Not Applicable
Mode of Action of Butyrate in the Human ColonIrritable Bowel Syndrome (IBS)HealthyNCT05249023Örebro University, Sweden37
Recruiting
Not Applicable
Molecular diagnositcs of colon cancerKCT0002703MD Healthcare350
Recruiting
Not Applicable
Gastrointestinal Biomarkers in Tissue and Biological Fluid Samples From Colorectal Cancer PatientsPrecancerous ConditionColorectal CancerPancreatic CancerGastric CancerEsophageal CancerNCT00899626Vanderbilt University Medical Center5,000
Completed
Not Applicable
Blood and Tissue Sample Collection for Future Colon Cancer Biomarker Studies in Patients Undergoing ColonoscopyHealth Status UnknownColorectal CancerNCT00897403Vanderbilt University6,446
Completed
Not Applicable
Evaluation of biomarkers in the colonic mucosa using biopsy specimesuspected colorectal diseasesJPRN-UMIN000014378Department of Gastroenterology and Hepatology, Nagoya University Graduate School of Medicine100